About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Report Type
Organization
Disposition
Year
Month
Found 72804 record(s)
Req # A-2023-001388
Adverse Drug Reactions (ADRs). Report numbers: E2B_06758608, 001000647, E2B_06725619, E2B_06920034, E2B_06745245, E2B_06758044, E2B_02793560, E2B_06729415, 001071531, 001070296.Organization: Health Canada
May 2024
Req # A-2023-001390
Adverse Drug Reactions (ADRs). Report numbers: 001059820, 001051355, 001043994, 001061093, E2B_06568436, E2B_05058863.Organization: Health Canada
May 2024
Req # A-2023-001426
Adverse Drug Reactions (ADRs) for Methotrexate. Report numbers: 001047194, 1046068. ADR for ASAPHEN. Report number: 001051189. ADR for Abiraterone acetate. Report number: E2B_06680076. ADR for Azithromycin. Report number: E2B_06624689. ADR for…Organization: Health Canada
May 2024
Req # A-2023-001428
Adverse Drug Reactions (ADRs). Report numbers: E2B_06809401, E2B_06773618.Organization: Health Canada
May 2024
Req # A-2023-001495
Adverse Drug Reactions (ADRs) for Entyvio. Report numbers: E2B_06833275, E2B_06803441, E2B_06770551, E2B_06831307, E2B_06796068, E2B_06807381. ADRs for Vedolizumab. Report numbers: E2B_06804360, E2B_06803544.Organization: Health Canada
May 2024
Req # A-2023-001496
Adverse Drug Reactions (ADRs) for Mesalazine. Report numbers: E2B_06771537, E2B_06833186, E2B_06833149,E2B_06812382, E2B_06812379, E2B_06833251, E2B_06823606, E2B_06803318. ADR for Pantoloc. Report number: 001067920.Organization: Health Canada
May 2024
Req # A-2023-001501
Adverse Drug Reactions (ADRs). Report numbers: E2B_03872373, 001071948, 001069783.Organization: Health Canada
May 2024
Req # A-2023-001517
Adverse Drug Reactions (ADRs). Report numbers: E2B_05722719, E2B_05431322, 001008866, E2B_05700268, E2B_05775676, E2B_05740647, E2B_05932577, E2B_05794671, E2B_05950522, E2B_05794672.Organization: Health Canada
May 2024
Req # A-2023-001518
Adverse Drug Reactions (ADRs). Report numbers: E2B_06416488, E2B_05982904, 000995799, 000995417, E2B_06481181, 001051134, E2B_02566868 001013224, E2B_00685447, 001010349.Organization: Health Canada
May 2024
Req # A-2023-001548
Adverse Drug Reactions (ADRs). Report numbers: E2B_06756603, 001070018.Organization: Health Canada
May 2024